How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance

This publication has 6 references indexed in Scilit:

• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
  Blood, 2008
• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
  The Lancet, 2007
• Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
  Leukemia, 2006
• Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment
  Leukemia, 2006
• Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
  Cell Death & Differentiation, 2003
• Campath-1H–Induced Complete Remission of Chronic Lymphocytic Leukemia despitep53Gene Mutation and Resistance to Chemotherapy
  New England Journal of Medicine, 2002